Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04018274 · ClinicalTrials.gov registry record · Phase 1

Effect of PF-06651600 on the Pharmacokinetics of Oral Contraceptive Steroids

A Phase 1 study, sponsored by Pfizer.

Completed
Registry status
Phase 1
Development phase
29
Enrollment target

NCT04018274 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 29 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04018274, a Phase 1 study, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 1
Development phase
29 participants
Enrollment target

Study Summary

This is a Phase 1, randomized, 2 way crossover, open-label study of the effect of multiple-dose PF 06651600 on single-dose oral contraceptive (OC) pharmacokinetics (PK) in healthy female subjects. Subjects will be randomized to 1 of 2 treatment sequences. A total of 28 healthy female subjects (14 in each treatment sequence) will be enrolled in the study. Each treatment sequence will consist of 2 periods.

Interventions

  • DRUG PF-06651600
  • DRUG Ethinyl estradiol (EE) and levonorgestrel(LN)

Trial Details

FieldValue
Enrollment Target 29 participants
Start Date 2019-08-09
Est. Completion 2019-10-16
Phase Phase 1

Sponsor

Pfizer

1,845 total trials

What the Registry Record Tells You About NCT04018274

The ClinicalTrials.gov registry entry for NCT04018274 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which PF-06651600 is the first listed.

NCT04018274 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04018274 about?

NCT04018274 is a clinical study titled "Effect of PF-06651600 on the Pharmacokinetics of Oral Contraceptive Steroids". This is a Phase 1, randomized, 2 way crossover, open-label study of the effect of multiple-dose PF 06651600 on single-dose oral contraceptive (OC) pharmacokinetics (PK) in healthy female subjects. Subjects will be randomized to 1 of 2 treatment sequences. A total of 28 healthy female subjects (14 in...

What is the current status of trial NCT04018274?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2019-08-09. Estimated completion is 2019-10-16.

What interventions are being tested in trial NCT04018274?

The interventions under investigation include: PF-06651600 (DRUG), Ethinyl estradiol (EE) and levonorgestrel(LN) (DRUG).

Who is sponsoring clinical trial NCT04018274?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.